NASDAQ:OGIOrganiGram Stock Price, Forecast & News

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OGI shares have decreased by 7.0% and is now trading at $1.60. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for OrganiGram.

OrganiGram is scheduled to release its next quarterly earnings announcement on Monday, July 20th 2020. View our earnings forecast for OrganiGram.

OrganiGram Holdings Inc (NASDAQ:OGI) issued its quarterly earnings results on Tuesday, April, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.01. The company earned $27.30 million during the quarter, compared to analysts' expectations of $25.07 million. OrganiGram had a negative net margin of 45.14% and a negative return on equity of 5.33%. OrganiGram's revenue was down 18.3% on a year-over-year basis. View OrganiGram's earnings history.

12 Wall Street analysts have issued 1-year price targets for OrganiGram's stock. Their forecasts range from $1.72 to $12.00. On average, they anticipate OrganiGram's share price to reach $6.46 in the next twelve months. This suggests a possible upside of 303.9% from the stock's current price. View analysts' price targets for OrganiGram.

Headlines about OGI stock have trended very negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. OrganiGram earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about OrganiGram.

Some companies that are related to OrganiGram include Aimmune Therapeutics (AIMT), BioXcel Therapeutics (BTAI), Phibro Animal Health (PAHC), Amphastar Pharmaceuticals (AMPH), Humanigen (HGEN), Enanta Pharmaceuticals (ENTA), Legend Biotech (PLRX), Rhythm Pharmaceuticals (RYTM), Passage Bio (ORIC), Nabriva Therapeutics (NBRV), Phathom Pharmaceuticals (PHAT), Arcturus Therapeutics (ARCT), G1 Therapeutics (GTHX), Retrophin (RTRX) and Gossamer Bio (GOSS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), KushCo (KSHB), Aphria (APHA), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Innovative Industrial Properties (IIPR), NVIDIA (NVDA) and Alibaba Group (BABA).

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OGI stock can currently be purchased for approximately $1.60.

OrganiGram has a market capitalization of $281.12 million and generates $61.27 million in revenue each year. The company earns $-7,200,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. OrganiGram employs 615 workers across the globe.

The official website for OrganiGram is www.organigram.ca.

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.